- Home
- GAME vs CELU Comparison
GAME vs CELU Comparison
Compare GAME & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | CELU |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.2M | 56.7M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | GAME | CELU |
|---|---|---|
| Price | $0.55 | $1.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.9M | 62.6K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $102,810,388.00 | $40,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.44 | $76.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 188.95 | N/A |
| 52 Week Low | $0.42 | $1.00 |
| 52 Week High | $2.87 | $4.35 |
Technical Indicators
Market Signals| Indicator | GAME | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 42.78 |
| Support Level | $0.48 | $1.62 |
| Resistance Level | $0.56 | $2.01 |
| Average True Range (ATR) | 0.04 | 0.12 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 83.97 | 19.84 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.